Publication: Drug-induced stevens-johnson syndrome and toxic epidermal necrolysis call for optimum patient stratification and theranostics via pharmacogenomics
Issued Date
2018-08-31
Resource Type
ISSN
1545293X
15278204
15278204
Other identifier(s)
2-s2.0-85053416459
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Annual Review of Genomics and Human Genetics. Vol.19, (2018), 329-353
Suggested Citation
Chonlaphat Sukasem, Theodora Katsila, Therdpong Tempark, George P. Patrinos, Wasun Chantratita Drug-induced stevens-johnson syndrome and toxic epidermal necrolysis call for optimum patient stratification and theranostics via pharmacogenomics. Annual Review of Genomics and Human Genetics. Vol.19, (2018), 329-353. doi:10.1146/annurev-genom-083115-022324 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/45075
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Drug-induced stevens-johnson syndrome and toxic epidermal necrolysis call for optimum patient stratification and theranostics via pharmacogenomics
Abstract
Copyright © 2018 by Annual Reviews. All rights reserved. The Global Genomic Medicine Collaborative, a multinational coalition of genomic and policy experts working to implement genomics in clinical care, considers pharmacogenomics to be among the first areas in genomic medicine that can provide guidance in routine clinical practice, by linking genetic variation and drug response. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe life-threatening reactions to medications with a high incidence worldwide. Genomic screening prior to drug administration is a key opportunity and potential paradigm for using genomic medicine to reduce morbidity and mortality and ultimately eliminate one of the most devastating adverse drug reactions. This review focuses on the current understanding of the surveillance, pathogenesis, and treatment of SJS/TEN, including the role of genomics and pharmacogenomics in the etiology, treatment, and eradication of preventable causes of drug-induced SJS/TEN. Gaps, unmet needs, and priorities for future research have been identified for the optimal management of drug-induced SJS/TEN in various ethnic populations. Pharmacogenomics holds great promise for optimal patient stratification and theranostics, yet its clinical implementation needs to be cost-effective and sustainable.